Home Investor Relations

Press Release

USFDA approval for Acetaminophen Extended-Release Tablets USP, 650 mg (OTC)
News Release August 2021
News Release May 2021
News Release September 2020
Metformin Hydrochloride Extended Release Tablets, USP 500 mg & 750 mg
News Release June 2020
Clarification on news circulating through WhatsApp
Metformin Extended Release Tablets 500 mg
News Release March 2020
Metformin Extended Release Tablets 500 mg & 750 mg
News Release December 2019
News Release September 2019
News Release June 2019
Receipt of Establishment Inspection Report (EIR) from the US FDA
Performance Highlight – Consolidated Q4 2018-19
US FDA Audit Update
Performance Highlight - Consolidated Q3 2018-19
Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine
5mg / 5ml Oral Solution
Performance Highlight – Consolidated for H1 2018-19
Performance Highlight – Consolidated Q1 2018-19
Transfer of Shares in dematerialised form only
Performance Highlight – Consolidated Q4 2017-18
Performance Highlight – Consolidated Q3 2017-18
Performance Highlight - Consolidated for H1 2017-18
Performance Highlight - Consolidated Q1 2017-18
Receipt of Establishment Inspection Report
Performance Highlights - Consolidated
Marksans Pharma Limited - US FDA
Marksans Pharma Limited Announcement
Performance Highlights - Consolidated
Performance Highlights - Consolidated
Performance Highlights - Consolidated
Performance Highlights - Consolidated
Marksans Pharma Limited announces USFDA approval for Metformin Hydrochloride Extended Release
News Release March 2016
News Release February 2016
News Release January 2016
News Release November 2015
News Release August 2015
News Release June 2015
News Release May 2015
News Release February 2015
News Release September 2014
Proceedings of 22nd AGM
Report of the Scrutinizer
Addendum to Notice of 22nd Annual General Meeting
News Release June 14